Among the 1680 ovarian serous cystadenocarcinoma patients, only 89 (5.3%) had mutations in the ST14 gene (Fig. 5A, B), and the type and frequency were as follows: amplification, 64 cases (3.8%); deep mutation, 17 cases (1.0%); missense mutation (unknown significance), eight cases (0.5%). Here, ST14 is linked to ovarian serous cystadenocarcinoma.